WaveMan
WaveMan · Company
MCRB · Seres Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MCRB Seres Therapeutics (MCRB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001609809
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · no price filed

What the filings say about MCRB

Insiders, 180 days
-$5.8K net sold
4 sellers · 0% of sales under a 10b5-1 plan

Seres Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Seres Therapeutics, Inc. insiders sold a net $5.8K of stock across 71 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
DesRosier Thomas
See Remarks
SELL
2026-08-18 SECtraded 2026-08-17
82
$373
-57.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 18, 2026.
  • The trade is 1.0% of the 8,117 shares held after it.
  • 3 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks DesRosier Thomas sold about $373 of MCRB on Aug 17, 2026; 3 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Henn Matthew R
See Remarks
SELL
2026-08-18 SECtraded 2026-08-17
81
$369
-57.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 18, 2026.
  • The trade is 1.0% of the 7,995 shares held after it.
  • 3 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Henn Matthew R sold about $369 of MCRB on Aug 17, 2026; 3 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Shaff Eric D.
Director
SELL
2026-08-18 SECtraded 2026-08-17
263
$1.2K
-57.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 18, 2026.
  • The trade is 2.1% of the 12,499 shares held after it.
  • 3 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shaff Eric D. sold about $1.2K of MCRB on Aug 17, 2026; 3 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Brady Kelly
See Remarks
SELL
2026-08-18 SECtraded 2026-08-17
64
$291
-57.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 18, 2026.
  • The trade is 0.7% of the 8,679 shares held after it.
  • 3 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Brady Kelly sold about $291 of MCRB on Aug 17, 2026; 3 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Shaff Eric D.
Director
SELL
2026-05-19 SECtraded 2026-05-18
259
$2.0K
-74.2%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Feb 15, 2026.
  • The trade is 2.2% of the 12,040 shares held after it.
  • 3 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shaff Eric D. sold about $2.0K of MCRB on May 18, 2026; 3 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
71 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 66 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.8K over 180 days
-$2.2K over 90 days
more than 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 5.2 days to cover · settled 2026-09-30
below 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MCRB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-88.8%12M
-89%-39%+11%+61%2025-102025-122026-022026-042026-062026-082026-10 2025-11-15 · Henn Matthew R sold $21.7K2025-11-15 · Young Teresa L. sold $18.0K2025-11-15 · Shaff Eric D. sold $3.8K2026-02-15 · Shaff Eric D. sold $2.2K2026-05-18 · Shaff Eric D. sold $2.0K2025-11-15 · DesRosier Thomas sold $1.3K2026-08-17 · Shaff Eric D. sold $1.2K2026-02-15 · Henn Matthew R sold $7542026-02-15 · DesRosier Thomas sold $6612026-02-15 · Young Teresa L. sold $6352026-05-18 · DesRosier Thomas sold $5952026-05-18 · Henn Matthew R sold $5802026-05-18 · Brady Kelly sold $4442026-08-17 · DesRosier Thomas sold $3732026-08-17 · Henn Matthew R sold $3692026-08-17 · Brady Kelly sold $291
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MCRB: institutional holders (13F)

13F holdings, latest reported quarter
Flagship Pioneering, LLC
1,155,850 sh
$9.1M
VANGUARD CAPITAL MANAGEMENT LLC
287,776 sh
$2.3M
MARSHALL WACE, LLP
172,245 sh
$1.4M
Vontobel Holding Ltd.
122,975 sh
$970.3K
BlackRock, Inc.
111,000 sh
$875.8K

Congress trades in MCRB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MCRB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MCRB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$59.2K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$200.3K position · as of 2026-06-30
0.0%
WisdomTree U.S. SmallCap Fund
$55.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$13.3K position · as of 2026-06-30
0.0%
Invesco RAFI US 1500 Small-Mid ETF
$62.4K position · as of 2026-07-31
0.0%
Avantis U.S. Small Cap Equity ETF
$38.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
2
Phase 3
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$4.0M
$1.6M
$1.7M
+62%
n/a
2021
$9.7M
-$10.7M
$4.4M
+141%
n/a
2020
$3.1M
$27.7M
$3.4M
+610%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $5.8K sold by insiders over 180 days, 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MCRB financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-1,193%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$51.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
3.19x
long-term debt only, 2024-06-30 (24 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.47x
TTM operating cash flow over long-term debt only, 2024-06-30 (24 months older than the period end)
Return on equity
-66.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-18.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-86.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$114.1M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2024-06-30 (24 months older than the period end), minus cash 2026-06-30
FCF yield
-260.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$789.0K$0$126.3M$7.1M
Operating income-$94.0M-$121.3M-$195.1M-$179.9M
Net income$5.7M$136.0K-$113.7M-$250.2M
EPS (diluted)0.640.00-17.77-2.31
Operating cash flow$1.1M-$148.6M-$117.4M-$228.8M
Cash$45.8M$30.8M$128.0M$163.0M
Long-term debtn/an/a$110.0M$50.0M
SEC XBRL, fiscal years, as known on 2026-10-28

MCRB Stock Sonar score 5/7 axes

Find similar shapesCompare

MCRB ranks highest on risk and compliance (60th percentile) and profitability (48th), and lowest on institutional and government (28th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
48
Inputs
  • Return on equity-66.6% · 44 pct, sector of 545
  • Return on assets-18.3% · 68 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-86.4% · 30 pct, sector of 576
Financial health
33
Inputs
  • Debt to equity3.19x · 5 pct, sector of 352
  • Cash flow to debt-0.47x · 60 pct, sector of 371
Insider conviction
30
Inputs
  • Net Form 4 buying (codes P and S), 180d-$6K · 60 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
28
Inputs
  • Funds adding, latest quarter16 · 28 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
60
Inputs
  • Short interest, % of float+3.6% · 65 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.8% · 55 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MCRB filings, in plain words

Are Seres Therapeutics insiders buying or selling MCRB?

In the 180 days to 2026-10-28, Seres Therapeutics insiders were net sellers, a net $5.8K across purchases and sales reported on Form 4, by 4 sellers.

Read the full summary

In the 180 days to 2026-10-28, Seres Therapeutics insiders were net sellers of MCRB, a net $5.8K across purchases and sales reported on Form 4 by 4 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies